Stay updated on DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Sign up to get notified when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.

Latest updates to the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Record History now shows a new revision entry, v3.6.3, replacing the previous v3.6.2. This reflects a minor site update to the study's record history rather than a change to trial details.SummaryDifference0.1%

- Check16 days agoChange DetectedThe Record History now includes a new Revision: v3.6.2 and removes Revision: v3.6.0, updating the history entries to reflect the latest release notes for the study record. This keeps the version history current without affecting study details.SummaryDifference0.1%

- Check30 days agoChange DetectedA new line 'No longer looking for participants' appears in the record history, signaling that recruitment for the study is closed. The history also includes a new 'Revision: v3.6.0' entry, while the previous 'Revision: v3.5.5' was removed.SummaryDifference0.4%

- Check37 days agoChange DetectedThe study record history now shows a new revision entry (v3.5.5) in place of the previous v3.5.4, representing an updated version of the study record.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4 to reflect a new release. This is a minor site update and does not alter the study record content.SummaryDifference0.1%

- Check73 days agoChange DetectedRecord History now shows a new revision labeled v3.5.3, replacing the previous v3.5.2 entry. This reflects an update to the study record's history metadata on the page.SummaryDifference0.2%

Stay in the know with updates to DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Enter your email address, and we'll notify you when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.